Get the Stockscreener App
23.28
2.24%
0.51
After Hours:
23.28
Catalyst Pharmaceuticals Inc stock is traded at $23.28, with a volume of 1.38M.
It is up +2.24% in the last 24 hours and up +8.63% over the past month.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).
See More
Previous Close:
$22.77
Open:
$22.68
24h Volume:
1.38M
Relative Volume:
0.97
Market Cap:
$2.86B
Revenue:
$460.48M
Net Income/Loss:
$142.80M
P/E Ratio:
19.73
EPS:
1.18
Net Cash Flow:
$221.79M
1W Performance:
+0.43%
1M Performance:
+8.63%
6M Performance:
-4.28%
1Y Performance:
+10.23%
1-Day Range:
$22.55
$23.62
1-Week Range:
$22.23
$23.62
52-Week Range:
$19.05
$26.58
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
Name
Catalyst Pharmaceuticals Inc
Sector
Industry
Phone
(305) 529-2522
Address
355 ALHAMBRA CIRCLE, CORAL GABLES
Compare CPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
23.28 | 2.80B | 460.48M | 142.80M | 221.79M | 1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-04-25 | Initiated | Robert W. Baird | Outperform |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Mar-14-24 | Initiated | Citigroup | Buy |
| Mar-07-24 | Initiated | BofA Securities | Buy |
| Dec-21-23 | Initiated | Oppenheimer | Outperform |
| Aug-24-22 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-07-18 | Resumed | Piper Jaffray | Overweight |
| Oct-05-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Apr-26-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Sep-30-14 | Reiterated | ROTH Capital | Buy |
| Sep-16-14 | Reiterated | ROTH Capital | Buy |
| Sep-15-14 | Reiterated | H.C. Wainwright | Buy |
| Oct-21-13 | Reiterated | Aegis Capital | Buy |
| Sep-24-13 | Initiated | Maxim Group | Buy |
| Sep-06-13 | Reiterated | Aegis Capital | Buy |
| Apr-18-13 | Initiated | Aegis Capital | Buy |
| Aug-27-12 | Upgrade | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| Oct-01-09 | Upgrade | Merriman | Sell → Neutral |
| May-29-09 | Downgrade | Hapoalim | Neutral → Underperform |
| May-29-09 | Downgrade | Merriman Curhan Ford | Buy → Sell |
| Dec-15-08 | Initiated | Merriman Curhan Ford | Buy |
| Nov-28-07 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jan-31-07 | Initiated | Stifel Nicolaus | Buy |
| Jan-05-07 | Initiated | First Albany | Buy |
View All
Catalyst Pharmaceuticals Inc Stock (CPRX) Latest News
Will Catalyst Pharmaceuticals Inc. (CN2) stock benefit from sector leadership2025 Investor Takeaways & High Accuracy Swing Entry Alerts - newser.com
Published on: 2025-11-21 01:33:23 - newser.com
Published on: 2025-11-20 09:43:10 - newser.com
Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2025 Deloitte Technology Fast 500 - The Globe and Mail
Published on: 2025-11-20 03:16:30 - newser.com
Why Catalyst Pharmaceuticals Inc. (CN2) stock is trending on social media2025 Buyback Activity & Daily Profit Maximizing Trade Tips - newser.com
How Catalyst Pharmaceuticals Inc. (CN2) stock stacks up against competitorsWeekly Market Summary & Fast Momentum Stock Entry Tips - newser.com
Relative strength of Catalyst Pharmaceuticals Inc. in sector analysisWeekly Trade Review & Free Technical Confirmation Trade Alerts - newser.com
What analyst consensus says on Catalyst Pharmaceuticals Inc. stockMarket Movers & Proven Capital Preservation Methods - newser.com
Why analysts maintain buy rating on Catalyst Pharmaceuticals Inc. (CN2) stockTrend Reversal & Stepwise Swing Trade Plans - newser.com
Why Catalyst Pharmaceuticals Inc. stock is considered a top pickEarnings Overview Summary & Weekly Top Stock Performers List - newser.com
Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2025 Deloitte Technology Fast 500™ - The Manila Times
Catalyst Pharmaceuticals (NASDAQ: CPRX) Ranks 304 on 2025 Deloitte Technology Fast 500 - Stock Titan
Published on: 2025-11-19 04:42:53 - newser.com
Is Catalyst Pharmaceuticals Inc. stock attractive for retirement portfoliosInsider Buying & Short-Term Trading Alerts - newser.com
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock - sharewise.com
Published on: 2025-11-19 00:40:27 - newser.com
Catalyst Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference - The Manila Times
Will Catalyst Pharmaceuticals Inc. stock split again soon2025 Risk Factors & Weekly Setup with ROI Potential - newser.com
Catalyst Pharmaceuticals Inc Stock (CPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):